Over 350 Brand-Name Drugs See a Price Increase in 2026

Jan 12, 2026 | Acquisition Cost Index (ACI) pricing, Biosimilars, Brand Name Drugs, Drug costs, High-value formulary, MedBen Rx, News, Patient assistance, Pharmacogenomics, Pharmacy

Pharmaceutical manufacturers are planning to raise list prices on at least 350 brand-name medications in the United States beginning in 2026, up from 250 drugs last year, according to new data from health care research firm 3 Axis Advisors. These increases reflect...

500+ Drugs Will See Price Increases in January

Jan 5, 2024 | Access solutions, Acquisition Cost Index (ACI) pricing, Appropriateness Solutions, Benefits preservation, Comparative Effectiveness, Drug costs, MedBen Rx, Pricing solutions, Specialty Drugs

Pfizer, Sanofi, Takeda Pharmaceutical, and other drugmakers will raise the prices of more than 500 drugs in early January, according to an analysis by health care researchers 3 Axis Advisors. Inflation and rising manufacturing costs will contribute to the price...